Retatrutide side effects were recorded in a real trial, which is rare here
It is also a Phase 2 dataset for a compound approved in no country at all. Nobody can prescribe it and no pharmacy can dispense it, so nothing recorded in that trial is available to you with a clinician attached to it. And a Phase 2 dataset limits what anyone can say. The most important harms in a drug's life are usually the ones a mid stage trial is not built to find, and this compound is still in the middle of the programme designed to find them.
The Phase 2 results published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues reported adverse events alongside the weight findings, as trials of this kind are required to do. Participants were monitored, events were recorded on a schedule, and the results were published.
That is worth stating plainly because the reflex on this site is to say that nobody has collected safety information. For this compound, in a trial setting, somebody did. Anyone who tells you the risk profile is entirely unknown is overstating, and the overstatement is unhelpful, because it makes the accurate limitations easier to dismiss.
What the published trial reported, and in whom
Gastrointestinal effects were the most commonly reported problem: nausea, vomiting, diarrhoea and constipation. They occurred in humans, in a supervised trial, and they were dose related, meaning they were more frequent at higher amounts.
This pattern is familiar across the drug class rather than peculiar to this compound. It is the reason the trial escalated amounts gradually over months instead of starting people at the top, and the reason clinicians were present with the authority to hold or reduce a step.
Two features of that setting deserve attention because they do not travel. The participants were screened, so people with conditions that would have made these effects dangerous were excluded before they started. And somebody was watching, so an effect that became severe had a route to being managed rather than endured.
What a 48 week phase 2 trial cannot find
Nothing in that table is a criticism of the trial. Phase 2 is not supposed to answer those questions, which is precisely why Phase 3 exists and why the TRIUMPH programme is running. What the table shows is how much of the safety picture is still being assembled while the compound is already being bought.
| Kind of harm | Could this trial detect it | Why |
|---|---|---|
| Common effects appearing early | Yes | Frequent enough to appear in this many humans, over this period |
| Dose related effects | Yes | The design compared several amounts against placebo |
| Uncommon serious events | Not reliably | Too few participants for a rare event to appear at all |
| Effects emerging after several years | No | The trial ran 48 weeks |
| Effects in excluded populations | No | Those humans were screened out by design |
| Interactions with other medicines | Only within the trial's rules | Participants were selected and their medications reviewed |
| Anything about an unverified vial | No | The trial used the manufacturer's product |
The risks that only exist outside a trial
Everything above concerns the drug. A grey market purchase adds a second category of risk that the trial has nothing to say about, because the trial did not contain it.
The product is unverified. Powder from a supplier no regulator inspects, sold with a statement that it is not for human consumption, dissolved by the buyer. Identity, strength and sterility rest on the seller's word, and independent testing across this category has repeatedly found material that did not match its label in both directions. A stronger than stated vial delivers an amount nobody chose.
Nobody has screened you. The conditions that would have excluded you from the trial are not checked, because there is nothing in the transaction that checks anything.
Nobody is watching. Gastrointestinal effects severe enough to cause dehydration are managed in a trial by people who notice. At home they are managed by the person experiencing them, at whatever hour they arrive.
And the reconstitution and measurement steps are yours. Those are ordinary sources of error that happen to careful people, which is why medicines are dispensed rather than mixed.
Where a report goes, in each of the three settings
Follow what happens to a serious event in each place, because the difference is stark.
In the trial, it is recorded within a defined window, reported to the sponsor, seen by a monitoring board, considered by a regulator, and eventually published. It contributes to the decision about whether this drug is approved and for whom.
With an approved medicine in the same class, it goes to a national reporting scheme, is aggregated with everyone else's, and can change a label or trigger a warning. Rare harms are found this way and essentially no other way.
With a vial bought online, it goes nowhere. There is no manufacturer with an obligation, no scheme collecting it, no clinician who prescribed it. Your experience does not join anybody else's, so no pattern can form, and the next person receives exactly the same reassurance you did.
That is why an absence of alarming reports from this market means so little. Nothing is set up to produce a report.
The interactions nobody is checking
One risk gets almost no attention outside a clinical setting and deserves some here.
A drug that acts on appetite, digestion and metabolism does not sit in isolation. Slowed stomach emptying can change how and when other oral medicines are absorbed. Substantial weight reduction alters the requirements for medicines whose amounts are tied to body size or to metabolic state, including treatments for blood pressure and for diabetes, where an unchanged amount can become the wrong amount as weight falls. Reduced food and fluid intake interacts with anything affected by dehydration.
A trial handles this by reviewing every participant's medication list and monitoring them. A prescriber of an approved medicine handles it with a leaflet, a record and a review appointment. A person buying online handles it by not knowing it is a question.
Anyone taking regular prescribed medication has the strongest reason on this page to talk to their own clinician, and doing so is not an admission of anything. A doctor being told what a patient is actually taking is the ordinary business of medicine.
The harm that is not a side effect at all
There is one risk in this market that no adverse event table would ever capture, and for some people it is the largest one.
Somebody with a serious weight related health problem, who has read the trial coverage and cannot obtain the compound legally, may spend a substantial sum on grey market vials over months. If the product is weak or is not what it claims, they get nothing. If it is genuine, they get an effect that reverses when the supply stops. Either way, the time and money went into a route with no clinician, no record and no follow up.
The alternative that was available throughout is the one the sales pages do not mention. Approved medicines acting on these pathways can be prescribed today, by a doctor, with a licence, a leaflet, a known manufacturer and a reporting scheme behind them. Bariatric surgery, structured weight management services and treatment of the conditions driving the weight are all real routes with evidence and accountability attached.
Whether any of those suits a particular person is a clinical conversation, not something a web page can settle. What a web page can point out is that the choice is not between an unapproved compound and nothing, which is how the market prefers to frame it.